Literature DB >> 1867901

Is routine mammography screening appropriate for women 40-49 years of age?

A B Miller1.   

Abstract

This article reviews the evidence about screening for breast cancer. Results are now available from four randomized trials--one quasi-experimental study and three case control studies. Only the oldest, the Health Insurance Plan (HIP) Trial, shows any evidence of mortality reduction in women from 40 to 49 years of age. However, the evidence from the HIP trial is weak and somewhat contradictory. Preliminary data from a further trial in Sweden and the National Breast Screening Study in Canada confirm my conclusion that the scientific evidence is insufficient at present to recommend mammography screening for women 40-49 years of age. This conclusion reinforces the decision of the U.S. Preventive Services Task Force, but contradicts the guidelines of the American Cancer Society and the National Cancer Institute.

Entities:  

Mesh:

Year:  1991        PMID: 1867901

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  4 in total

1.  Screening mammography and constructs from the transtheoretical model: Associations using two definitions of the stages-of-adoption.

Authors:  W Rakowski; B Ehrich; C E Dubé; D N Pearlman; M G Goldstein; K K Peterson; B K Rimer; H Woolverton
Journal:  Ann Behav Med       Date:  1996-06

2.  Update on mammography trends: comparisons of rates in 2000, 2005, and 2008.

Authors:  Nancy Breen; Jane F Gentleman; Jeannine S Schiller
Journal:  Cancer       Date:  2010-11-30       Impact factor: 6.860

3.  Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years.

Authors:  A B Miller; C J Baines; T To; C Wall
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

4.  Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.

Authors:  Stephen Duffy; Daniel Vulkan; Howard Cuckle; Dharmishta Parmar; Shama Sheikh; Robert Smith; Andrew Evans; Oleg Blyuss; Louise Johns; Ian Ellis; Peter Sasieni; Chris Wale; Jonathan Myles; Sue Moss
Journal:  Health Technol Assess       Date:  2020-10       Impact factor: 4.014

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.